ClinicalTrials.gg

Program

rosuvastatin

Also written as “Rosuvastatin”, “CKD-828, D097, D337” and “Rosuvastatin 20mg”.

Its studies are mostly in Hypercholesterolemia · Hypertension · Dyslipidemias · Hyperlipidemias · Coronary Artery Disease, led by 27 companies.

Furthest: phase 4, since Oct 7, 2005138 company-led studies, 8 open or runningNext primary completion: Jan 25, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca705 open or runningphase 4since Oct 7, 2005Sep 16, 2005Jan 25, 2027phase 1 · NCT07534592
Yuhan100 open or runningphase 4since Jul 12, 2017Jan 5, 2012none ahead
Chong Kun Dang Pharmaceutical80 open or runningphase 2since Nov 27, 2016Jan 24, 2014none ahead
Organon60 open or runningphase 4since Mar 31, 2008Aug 25, 2004none ahead
GlaxoSmithKline40 open or runningphase 1since Dec 18, 2008Dec 18, 2008none ahead
Merck41 open or runningphase 3since Oct 10, 2025Jun 17, 2015none ahead
Hanlim Pharm.30 open or runningphase 3since Jun 17, 2018Jun 17, 2018none ahead
IlDong Pharmaceutical30 open or runningphase 3since Mar 5, 2014Mar 5, 2014none ahead
Jeil Pharmaceutical30 open or runningphase 3since Jun 23, 2016Jul 4, 2014none ahead
Lotus Pharmaceutical30 open or runningphase 3since May 13, 2015Mar 4, 2014none ahead
Celltrion20 open or runningphase 3since Apr 27, 2026Jul 30, 2021none ahead
Daewon Pharmaceutical20 open or runningphase 3since Oct 12, 2016Oct 12, 2016none ahead
Daewoong Pharmaceutical20 open or runningphase 3since Nov 7, 2019Mar 14, 2014none ahead
Daiichi Sankyo20 open or runningphase 1since Sep 11, 2025Sep 11, 2025none ahead
Hanmi Pharmaceutical20 open or runningphase 1since Mar 9, 2014Mar 9, 2014none ahead
kobe-university20 open or runningphase 4since Jun 15, 2017Jun 15, 2017none ahead
LG Chem20 open or runningphase 3since Aug 5, 2013Aug 5, 2013none ahead
Ache Laboratorios Farmaceuticos10 open or runningphase 3since Aug 18, 2011Aug 18, 2011none ahead
d16-pharma-biotec-ltd10 open or runningphase 4since Jun 4, 2012Jun 4, 2012none ahead
Dong-A ST10 open or runningphase 4since Oct 29, 2014Oct 29, 2014none ahead
Hansoh Pharmaceutical Group11 open or runningphase 1since May 23, 2025May 23, 2025none ahead
HK inno.N10 open or runningphase 4since Nov 20, 2018Nov 20, 2018none ahead
hyundai-pharm11 open or runningphase 3since Oct 15, 2024Oct 15, 2024none ahead
Jiangsu HengRui Medicine10 open or runningphase 1since May 27, 2020May 27, 2020none ahead
NVP Healthcare10 open or runningphase 1since Nov 9, 2014Nov 9, 2014none ahead
pin-siang-medical-biotechnology-co-ltd10 open or runningno phasesince Nov 6, 2013Nov 6, 2013none ahead
verisfield-uk-ltd-greek-branch10 open or runningphase 1since May 9, 2016May 9, 2016none ahead

Also a collaborator on its studies: parexel, pharma-medica-research-inc, Pfizer, Regeneron Pharmaceuticals, impact-biomedicines-inc-a-wholly-owned-subsidiary-of-celgene, Eli Lilly, linical-korea and Shionogi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Oct 29, 2014.

  1. Dec 2, 2024Phase 3 study in DyslipidemiasAstraZeneca · NCT06834932 · 432 enrolled · China, Hong Kong
  2. Dec 16, 2024Phase 1 study in DyslipidemiasAstraZeneca · NCT06742853 · 81 enrolled · United States, United Kingdom
  3. May 23, 2025Hansoh Pharmaceutical Group's first study: phase 1 study in DyslipidemiasNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT07001787 · 88 planned
  4. Jul 17, 2025Phase 1 study in Healthy ParticipantsAstraZeneca · NCT07088913 · 20 enrolled · United States
  5. Sep 11, 2025Daiichi Sankyo's first studies: 2 phase 1 studies in Healthy SubjectsNew to Daiichi SankyoDaiichi Sankyo · NCT07182383, NCT07201545
  6. Oct 10, 2025Phase 3 study in HyperlipidemiasMerck · NCT07216482 · 996 enrolled · United States, Argentina, Australia and more
  7. Oct 27, 2025Phase 1 study in HealthyMerck · NCT07222098 · 16 enrolled · United States
  8. Dec 10, 2025Phase 1 study in HealthyMerck · NCT07300280 · 60 enrolled · United States
  9. Dec 19, 2025Phase 1 study in HyperlipidemiasAstraZeneca · NCT07316608 · 44 enrolled · United States
  10. Apr 10, 2026Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07534592 · 48 enrolled · United States
  11. Apr 27, 2026Phase 3 study in HypertensionPhase 3 reachedCelltrion · NCT07564726 · 163 enrolled · South Korea
  12. May 26, 20262 phase 3 studies in HypercholesterolemiaAstraZeneca · NCT07619131, NCT07619118
  13. Nov 5, 2026Phase 3 study in HypercholesterolemiaAstraZeneca · NCT07930507 · 204 planned · China, Hong Kong, Malaysia and more
  14. Nov 10, 2026Primary completion moved from 2026-10-01 to 2027-01-25Date moved laterphase 1 · +4 months · NCT07534592

Ahead

  1. Jan 25, 2027Primary completion: phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07534592
  2. Feb 22, 2027Primary completion: phase 3 study in DyslipidemiasAstraZeneca · NCT06834932
  3. May 28, 2027Primary completion: phase 3 study in HypercholesterolemiaAstraZeneca · NCT07619118
  4. Jul 30, 2027Primary completion: phase 3 study in HypercholesterolemiaAstraZeneca · NCT07619131

TargetBeta

HMGCR →read by rule
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule

Other programs on HMGCR

ProgramCompanyFurthest phaseStudies
AtorvastatinruleViatrisphase 4186
SimvastatinruleOrganonphase 4100
pitavastatinruleKowaphase 436

Studies

The newest 60 of 138 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07930507Hypercholesterolemia · China, Hong Kong, Malaysia and more3Not yet recruitingAstraZenecaOct 11, 2027204
NCT07619131Hypercholesterolemia · United States, Bulgaria, Canada and more3RecruitingAstraZenecaJul 30, 2027600
NCT07619118Hypercholesterolemia · United States, Australia, Canada and more3RecruitingAstraZenecaMay 28, 2027200
NCT07564726Hypertension · South Korea3CompletedCelltrionFeb 13, 2024163
NCT07534592Diabetes Mellitus, Type 2 · United States1Active, not recruitingAstraZenecaJan 25, 202748
NCT07316608Hyperlipidemias · United States1CompletedAstraZenecaJun 5, 202644
NCT07300280Healthy · United States1CompletedMerckOct 14, 202660
NCT07222098Healthy · United States1CompletedMerckDec 14, 202516
NCT07216482Hyperlipidemias · United States, Argentina, Australia and more3Active, not recruitingMerckAug 3, 2026996
NCT07201545Healthy Subjects · Portugal1CompletedDaiichi SankyoDec 10, 202558
NCT07182383Healthy Subjects · Portugal1CompletedDaiichi SankyoNov 24, 202558
NCT07088913Healthy Participants · United States1CompletedAstraZenecaFeb 20, 202620
NCT07001787Dyslipidemias1Not yet recruitingHansoh Pharmaceutical GroupFeb 202688
NCT06742853Dyslipidemias · United States, United Kingdom1CompletedAstraZenecaOct 29, 202581
NCT06834932Dyslipidemias · China, Hong Kong3Active, not recruitingAstraZenecaFeb 22, 2027432
NCT06646354Hypertension · Korea, Republic of3By invitationhyundai-pharmMay 19, 2025125
NCT06554821Healthy Participants · Germany1CompletedAstraZenecaOct 8, 202428
NCT06475872Primary Hypercholesterolemia · Korea, Republic of1CompletedHanlim Pharm.Dec 7, 202336
NCT06160414Healthy · United Kingdom1CompletedAstraZenecaFeb 5, 202420
NCT06112678Hypertension · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalFeb 19, 202463
NCT05768360Healthy Male Subjects · Germany1CompletedAstraZenecaJun 24, 20236
NCT05749861Hypertension · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalJun 7, 202365
NCT05549401Hypertension · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalNov 30, 202232
NCT05384262Dyslipidemias · United States, United Kingdom1CompletedAstraZenecaJun 14, 2024183
NCT05192356Hypertension · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalMay 8, 202263
NCT05002244Health, Subjective · Korea, Republic of1CompletedCelltrionAug 29, 202137
NCT04883658Hypertension · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalJul 20, 202162
NCT04659070Hypertension · Korea, Republic of3UNKNOWNHanlim Pharm.May 19, 2022156
NCT04428086Solid Tumor, Adult · China1CompletedJiangsu HengRui MedicineAug 22, 202119
NCT04258865Hypertension · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalApr 26, 202030
NCT04161001Hypertension · Korea, Republic of3UNKNOWNDaewoong PharmaceuticalNov 20, 2021237
NCT04158076Hypercholesterolemia · Korea, Republic of3CompletedYuhanJan 14, 2021131
NCT04056169Acute Coronary Syndrome · Korea, Republic of4CompletedYuhanJul 23, 201950
NCT03872232Hypercholesterolemia · Korea, Republic of3CompletedYuhanAug 12, 2020180
NCT03847506Hypertension · Korea, Republic of4CompletedHK inno.NDec 2, 2020127
NCT03657758Coronary Artery Disease · Japan4UNKNOWNkobe-universityAug 31, 202075
NCT03571087Primary Hypercholesterolemia3CompletedHanlim Pharm.Aug 2015374
NCT03566316Hypertension With Hyperlipidemia · Korea, Republic of3CompletedIlDong PharmaceuticalJun 16, 2017134
NCT03550859Renal Insufficiency, Chronic · Korea, Republic of4UNKNOWNYuhanDec 2021374
NCT03217409Diabetes Mellitus · Korea, Republic of4CompletedYuhanApr 3, 201985
NCT03192579Coronary Artery Disease Progression4Completedkobe-universityJun 2, 201750
NCT03019549Healthy · United States1CompletedAstraZenecaMay 22, 201742
NCT02977065Dyslipidemias · Australia2CompletedChong Kun Dang PharmaceuticalDec 30, 201762
NCT02963116High Risk Coronary Artery Disease · United Kingdom1CompletedAstraZenecaMar 1, 201712
NCT03210532Hypertension · Korea, Republic of3CompletedDaewon PharmaceuticalSep 2017129
NCT02933658Hypertension1CompletedDaewon PharmaceuticalNov 201571
NCT02951962Hypertension · Korea, Republic of1CompletedYuhanSep 201660
NCT02859129Hypertriglyceridemia · United States1CompletedAstraZenecaNov 2013114
NCT02827903Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedJeil PharmaceuticalNov 21, 2017237
NCT02767310Healthy · India1Completedverisfield-uk-ltd-greek-branchJun 201649
NCT02748057Hypercholesterolemia3CompletedOrganonDec 11, 2017135
NCT02741245Hypercholesterolemia3CompletedOrganonJan 18, 2017321
NCT02707224Healthy1CompletedLotus PharmaceuticalJun 201540
NCT02546323Atherosclerosis · China3CompletedAstraZenecaJan 29, 2019543
NCT02477514Skin Diseases, Bacterial1CompletedMerckAug 201518
NCT02445352Primary Hypercholesterolemia · Korea, Republic of3CompletedLotus PharmaceuticalJan 2015379
NCT02434497Homozygous Familial Hypercholesterolemia · Belgium, Canada, Denmark and more3CompletedAstraZenecaNov 17, 20169
NCT02387619Hypertension · Korea, Republic of1CompletedJeil PharmaceuticalMar 201541
NCT02289430Healthy1CompletedNVP HealthcareFeb 201559
NCT02280590Hyperlipidemias · Korea, Republic of4CompletedDong-A STJun 2015223

How it is read

Names in the registry

  • “Rosuvastatin”, 105 entries
  • “rosuvastatin”, 10 entries
  • “CKD-828, D097, D337”, 6 entries
  • “Rosuvastatin 20mg”, 6 entries
  • “Ezetimibe/Rosuvastatin”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.